ABSTRACT
This article discusses the complexities and various aspects related to the treatment of pregnant women with COVID-19. The experience of Chinese doctors who were the first to face this problem is considered, and a new method of treating the disease using the drug Baricitinib is also considered. Baricitinib is an anti-inflammatory drug, a representative of the Janus kinase class, used in the treatment of rheumatoid arthritis. It blocks intracellular signaling pathways, which leads to the regulation of the synthesis of interleukins 2, 6, 10, and interferon-gamma. The drug is licensed for the treatment of rheumatoid arthritis, has good efficacy and safety indicators. Attention was paid to the doses and modes of use of baricitinib. The article discusses a study conducted by Chinese doctors. The study involved 34 infected pregnant women, of whom half were offered standard treatment and the other half standard treatment with baricitinib. In order to have a complete picture that allows us to conclude that this method of treatment is ineffective or effective, it is necessary to continue monitoring patients who took baracitinib in the treatment of COVID-19.
ABSTRACT
Currently, intensive study of the clinical and epidemiological features of COVID-19 is continuing. In this regard, the development of new means of its prevention and treatment is becoming increasingly relevant. The most vulnerable category of people, along with older people, is pregnant women. Due to their low immune reactivity, they are more susceptible to severe complications than others. In this article, we conducted a retrospective analysis of 280 case histories of pregnant women living in Republics of the North Caucasus Federal District of the Russian Federation (the Republic of Ingushetia, the Republic of Dagestan and the Republic of North Ossetia-Alania) who received medical care in 2021 with an officially confirmed diagnosis of mild and moderate COVID-19 coronavirus infection. Analyzing the pregnancy outcomes in patients with COVID-19, we found that 15.3% of women were delivered through the natural birth canal, 10.7% of women in labor due to an increase in respiratory failure and, as a consequence, fetal hypoxia, were delivered by caesarean section. 2.5% of cases ended in spontaneous abortion in the first trimester. 71.4% of pregnant women who underwent COVID-19 were hospital discharged with progressive pregnancy at different gestation periods. As a result of the work carried out, we analyzed a number of clinical and laboratory data in pregnant women with COVID-19 in dynamics assessed the course of the disease in different periods of pregnancy by region and assessed the effectiveness of pharmacotherapy.